High SLC1A5 expression levels could facilitate tumor proliferation and antioxidant capacity and are associated with poor prognosis and the ability to resist dasatinib, sunitinib, sorafenib, and imatinib treatment in several malignancies [2–5]. Here, SLC1A5 is linked to neoplasm.